<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Site Qualification Report - Site 123</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            margin: 40px;
            color: #333;
        }
        h1 {
            color: #1a5276;
            border-bottom: 2px solid #3498db;
            padding-bottom: 10px;
        }
        h2 {
            color: #2874a6;
            margin-top: 30px;
        }
        h3 {
            color: #2e86c1;
        }
        .content {
            max-width: 800px;
            margin: 0 auto;
        }
        ul {
            margin-left: 20px;
        }
        li {
            margin-bottom: 8px;
        }
        .header {
            text-align: center;
            margin-bottom: 40px;
        }
        .footer {
            margin-top: 50px;
            border-top: 1px solid #ddd;
            padding-top: 20px;
            font-size: 12px;
            color: #777;
            text-align: center;
        }
        .note {
            background-color: #f8f9fa;
            border-left: 4px solid #3498db;
            padding: 10px 15px;
            margin: 20px 0;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 20px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 8px;
            text-align: left;
        }
        th {
            background-color: #f2f2f2;
        }
        .summary {
            background-color: #f8f9fa;
            padding: 20px;
            border-radius: 5px;
            margin: 20px 0;
        }
        .rating {
            font-weight: bold;
        }
        .good {
            color: green;
        }
        .average {
            color: orange;
        }
        .poor {
            color: red;
        }
    </style>
</head>
<body>
    <div class="content">
        <div class="header">
            <h1>Site Qualification Report</h1>
            <p>Protocol: PRO001</p>
            <p>Site ID: 123</p>
            <p>Date of Visit: November 5, 2024</p>
        </div>

        <div class="summary">
            <h2>Executive Summary</h2>
            <p>Site 123 (Diabetes Research Center, Philadelphia) was evaluated for participation in Protocol PRO001. Overall, the site demonstrates <span class="rating good">strong</span> capabilities to conduct the study with adequate facilities, experienced staff, and access to the target patient population.</p>
            
            <p><strong>Recommendation:</strong> <span class="rating good">Approved</span> for study participation with an initial enrollment target of 20 patients.</p>
        </div>

        <h2>1. Site Information</h2>
        <table>
            <tr>
                <th>Site Name</th>
                <td>Diabetes Research Center</td>
            </tr>
            <tr>
                <th>Address</th>
                <td>123 Medical Drive, Philadelphia, PA 19104</td>
            </tr>
            <tr>
                <th>Principal Investigator</th>
                <td>Dr. John Williams, MD</td>
            </tr>
            <tr>
                <th>Sub-Investigators</th>
                <td>Dr. Sarah Chen, MD<br>Dr. Robert Johnson, MD</td>
            </tr>
            <tr>
                <th>Study Coordinator</th>
                <td>Maria Rodriguez, RN</td>
            </tr>
            <tr>
                <th>Phone</th>
                <td>(215) 555-1234</td>
            </tr>
            <tr>
                <th>Email</th>
                <td>jwilliams@diabetesresearch.org</td>
            </tr>
        </table>

        <h2>2. Investigator Experience</h2>
        <p>Dr. Williams has served as PI on 15 clinical trials in the past 5 years, including 8 diabetes studies. The site has participated in 3 studies with our company previously, completing all with good enrollment and data quality metrics.</p>
        
        <h3>2.1 Investigator Qualifications</h3>
        <ul>
            <li>Board certified in Endocrinology</li>
            <li>20 years of clinical experience in diabetes management</li>
            <li>Published 24 peer-reviewed articles in the field</li>
            <li>Current on GCP training (completed August 2024)</li>
            <li>No disqualifications or restrictions from regulatory authorities</li>
        </ul>
        
        <h3>2.2 Staff Experience and Training</h3>
        <table>
            <tr>
                <th>Staff Member</th>
                <th>Role</th>
                <th>Experience</th>
                <th>GCP Training</th>
            </tr>
            <tr>
                <td>Dr. Sarah Chen</td>
                <td>Sub-Investigator</td>
                <td>8 clinical trials</td>
                <td>Current (July 2024)</td>
            </tr>
            <tr>
                <td>Dr. Robert Johnson</td>
                <td>Sub-Investigator</td>
                <td>5 clinical trials</td>
                <td>Current (September 2024)</td>
            </tr>
            <tr>
                <td>Maria Rodriguez</td>
                <td>Study Coordinator</td>
                <td>12 clinical trials</td>
                <td>Current (May 2024)</td>
            </tr>
            <tr>
                <td>Jennifer Thompson</td>
                <td>Research Nurse</td>
                <td>7 clinical trials</td>
                <td>Current (October 2024)</td>
            </tr>
            <tr>
                <td>Michael Davis</td>
                <td>Laboratory Technician</td>
                <td>10 clinical trials</td>
                <td>Current (June 2024)</td>
            </tr>
        </table>

        <h2>3. Patient Population</h2>
        <p>The site has access to a substantial patient population matching the study criteria. Dr. Williams reported seeing approximately 250 patients with type 2 diabetes per month in the clinic.</p>
        
        <h3>3.1 Recruitment Capabilities</h3>
        <ul>
            <li>Electronic medical records system with search capability for identifying eligible patients</li>
            <li>Database of approximately 1,800 type 2 diabetes patients</li>
            <li>Established referral network with 5 local primary care practices</li>
            <li>Previous successful recruitment strategy including social media and local newspaper advertisements</li>
            <li>Historical enrollment rate of 3-5 patients per month for similar studies</li>
        </ul>
        
        <h3>3.2 Competing Studies</h3>
        <p>The site is currently participating in two other diabetes clinical trials:</p>
        <ul>
            <li>Study ABC-123: Investigating a SGLT-2 inhibitor (enrollment complete, in follow-up phase)</li>
            <li>Study XYZ-789: Investigating a DPP-4 inhibitor (different patient population, minimal overlap expected)</li>
        </ul>
        <p>Dr. Williams confirmed that these studies will not compete significantly with the PRO001 trial, as they target different patient populations or are in later stages.</p>

        <h2>4. Facilities and Equipment</h2>
        
        <h3>4.1 Clinical Space</h3>
        <ul>
            <li>Dedicated research area with 4 examination rooms</li>
            <li>Private area for patient consenting</li>
            <li>Secure storage for study materials</li>
            <li>Comfortable waiting area with capacity for 10-12 patients</li>
            <li>Meeting room for monitoring visits and staff training</li>
        </ul>
        
        <h3>4.2 Equipment</h3>
        <table>
            <tr>
                <th>Equipment</th>
                <th>Quantity</th>
                <th>Calibration Status</th>
                <th>Condition</th>
            </tr>
            <tr>
                <td>Refrigerator (-2° to 8°C)</td>
                <td>2</td>
                <td>Current (October 2024)</td>
                <td>Excellent</td>
            </tr>
            <tr>
                <td>Freezer (-20°C)</td>
                <td>1</td>
                <td>Current (September 2024)</td>
                <td>Good</td>
            </tr>
            <tr>
                <td>ECG Machine</td>
                <td>2</td>
                <td>Current (August 2024)</td>
                <td>Excellent</td>
            </tr>
            <tr>
                <td>Centrifuge</td>
                <td>2</td>
                <td>Current (July 2024)</td>
                <td>Good</td>
            </tr>
            <tr>
                <td>Scales</td>
                <td>4</td>
                <td>Current (October 2024)</td>
                <td>Excellent</td>
            </tr>
            <tr>
                <td>Blood Pressure Equipment</td>
                <td>6</td>
                <td>Current (September 2024)</td>
                <td>Excellent</td>
            </tr>
            <tr>
                <td>Temperature Monitoring System</td>
                <td>1 system</td>
                <td>Current (October 2024)</td>
                <td>Excellent</td>
            </tr>
        </table>
        
        <h3>4.3 Laboratory Facilities</h3>
        <p>The site has an on-site CLIA-certified laboratory capable of performing all protocol-required local laboratory tests. The laboratory participates in external quality control programs and maintains appropriate certifications.</p>
        
        <h3>4.4 Pharmacy</h3>
        <p>The site has a dedicated research pharmacy with:</p>
        <ul>
            <li>Controlled access limited to authorized personnel</li>
            <li>Temperature-monitored storage facilities</li>
            <li>Computerized inventory management system</li>
            <li>Dedicated pharmacist with clinical trial experience</li>
        </ul>

        <h2>5. Standard Operating Procedures</h2>
        <p>The site maintains comprehensive SOPs covering all aspects of clinical trial conduct, including:</p>
        <ul>
            <li>Informed consent process</li>
            <li>Source documentation</li>
            <li>Adverse event reporting</li>
            <li>Drug accountability</li>
            <li>Sample handling and processing</li>
            <li>Data entry and query resolution</li>
            <li>Essential document maintenance</li>
        </ul>
        <p>All SOPs were reviewed and found to be current, with the last revision within the past 12 months.</p>

        <h2>6. Quality Assurance</h2>
        <p>The site has established quality control procedures including:</p>
        <ul>
            <li>Regular internal audits of study documentation</li>
            <li>Weekly team meetings to review study progress and address issues</li>
            <li>Training program for all staff involved in clinical research</li>
            <li>Process for handling protocol deviations and implementing corrective actions</li>
        </ul>
        <p>The site underwent an FDA inspection in May 2024 with no significant findings.</p>

        <h2>7. Areas for Improvement</h2>
        <p>While the site is well-qualified overall, the following areas could be strengthened:</p>
        <ul>
            <li>Additional training on the specific requirements for HbA1c sample processing is recommended</li>
            <li>Consider designating a backup study coordinator to ensure coverage during planned absences</li>
            <li>Update the site's participant retention strategy to address potential challenges with the 24-week follow-up period</li>
        </ul>

        <h2>8. Conclusion and Recommendations</h2>
        <p>Site 123 meets all requirements to participate in Protocol PRO001. The investigator and staff are experienced, the facilities are appropriate, and the site has access to a suitable patient population.</p>
        
        <p><strong>Specific recommendations:</strong></p>
        <ul>
            <li>Approve site with initial enrollment target of 20 patients</li>
            <li>Provide additional training on HbA1c sample processing during site initiation visit</li>
            <li>Schedule first monitoring visit within 2 weeks of first patient enrollment</li>
            <li>Assist site in developing enhanced retention strategies for 24-week follow-up</li>
        </ul>

        <div class="footer">
            <p>Report prepared by: James Wilson, Clinical Research Associate</p>
            <p>Approved by: Susan Taylor, Clinical Trial Manager</p>
            <p>© 2025 Clinical Research Organization. All rights reserved.</p>
        </div>
    </div>
</body>
</html>